Jaguar health reports approval of all proposals at june 2024 annual meeting of stockholders

Jaguar to report pivotal phase 3 ontarget trial results for its cancer supportive care drug crofelemer on or before july 23, 2024 investor webcast on or before july 23 will include updates on jaguar's cancer supportive care portfolio, including participation from jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea and oral mucositis in honor of world rainforest day (june 22), jaguar is proud to share realpharma podcast interview with ethnobotanist dr. steven king san francisco, ca / accesswire / june 21, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced the voting results of the company's annual meeting of stockholders held june 21, 2024 (the "annual meeting"). five proposals were submitted to and approved by the stockholders of the company at the annual meeting.
JAGX Ratings Summary
JAGX Quant Ranking